Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Will Abbott, which is expanding into comprehensive healthcare centered on FreeStyle Libre, or DexCom, which is aiming for high growth and high profitability as a CGM specialist, prevail?]Record Date: ...
【FreeStyle Libreを軸に総合ヘルスケアへ広げるAbbottか、CGM専業で高成長・高収益化を狙うDexComか】 記録日：2026年9月9日 株価・バリュエーションは、米国市場の直近取引日である2026年9月8日終値を基準としています。 Abbott LaboratoriesはNYSE上場（ABT）、DexCom, Inc.はNASDAQ上場（DXCM）です。両社とも12月決算、会計 ...
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...
Abbott Laboratories ABT and DexCom DXCM are two of the most prominent players in the continuous glucose monitoring (CGM) space. Abbott has continued to enhance its continuous monitoring portfolio ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
With the rising prevalence of diabetes worldwide, the demand for more efficient and real-time glucose monitoring solutions has intensified. AbbottABT and DexCom DXCM are among the leading players in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results